Employing
a virtual screening approach, we identified the pyroglutamide
moiety as a nonacid replacement for the cyclohexanecarboxylic acid
group which, when coupled to our previously reported conformationally
locked tricyclic core, provided potent and selective RORγt inverse
agonists. Structure–activity relationship optimization of the
pyroglutamide moiety led to the identification of compound 18 as a potent and selective RORγt inverse agonist, albeit with
poor aqueous solubility. We took advantage of the tertiary carbinol
group in 18 to synthesize a phosphate prodrug, which
provided good solubility, excellent exposures in mouse PK studies,
and significant efficacy in a mouse model of psoriasis.